Literature DB >> 33472525

System degeneration in an MM1-type sporadic Creutzfeldt-Jakob disease case with an unusually prolonged akinetic mutism state.

Yasushi Iwasaki1, Keiko Mori2, Masumi Ito2, Yoshinari Kawai2, Akio Akagi1, Yuichi Riku1, Hiroaki Miyahara1, Atsushi Kobayashi3, Tetsuyuki Kitamoto4, Mari Yoshida1.   

Abstract

Methionine/methionine type 1 (MM1-type) sporadic Creutzfeldt-Jakob disease (sCJD), known as the 'classic type,' shows typical clinicopathological sCJD findings. In general, patients reach an akinetic mutism state within a few months of disease onset and die soon after if supportive therapies are not administered. Here, we describe remarkable neuropathologic observations of MM1-type sCJD in a 48-year-old, Japanese man with an unusually prolonged akinetic mutism state. In the early disease stages, the patient exhibited abnormal behaviour with gait disturbance and rapidly progressive cognitive dysfunction. Diffusion-weighted magnetic resonance imaging revealed extensive cerebral cortical hyperintensity. Prion protein (PrP) gene analysis revealed no mutations, and the polymorphic codon 129 exhibited methionine homozygosity. Although the patient remained stable with tube feeding for more than 2 years after reaching the akinetic mutism state, he died because of central respiratory failure 30 months after disease onset. Neuropathologic investigation showed extensive devastating lesions, such as status spongiosus, and typical spongiform changes could no longer be observed in the cerebral neocortex. Conspicuous pyramidal tract degeneration was observed. However, the regions commonly preserved in MM1-type sCJD pathology were still relatively preserved. Immunostaining revealed extensive diffuse synaptic-type PrP deposition in the grey matter. The pathological findings suggested that sCJD is a neurodegenerative disease that shows system degeneration; there are primary and secondary degenerative regions and distinct preserved regions, even in cases with prolonged disease duration. In addition, it is considered that there is a limited survival period for MM1-type sCJD, even if active symptomatic treatment is provided.

Entities:  

Keywords:  Creutzfeldt-Jakob disease; akinetic mutism state; panencephalopathic-type; pyramidal tract degeneration; system degeneration

Mesh:

Substances:

Year:  2021        PMID: 33472525      PMCID: PMC7833778          DOI: 10.1080/19336896.2020.1868931

Source DB:  PubMed          Journal:  Prion        ISSN: 1933-6896            Impact factor:   3.931


  18 in total

1.  Clinicopathologic characteristics of sporadic Japanese Creutzfeldt-Jakob disease classified according to prion protein gene polymorphism and prion protein type.

Authors:  Yasushi Iwasaki; Mari Yoshida; Yoshio Hashizume; Tetsuyuki Kitamoto; Gen Sobue
Journal:  Acta Neuropathol       Date:  2006-07-18       Impact factor: 17.088

2.  Autopsy case of sporadic Creutzfeldt-Jakob disease presenting with signs suggestive of brainstem and spinal cord involvement.

Authors:  Yasushi Iwasaki; Masahiro Iijima; Seigo Kimura; Mari Yoshida; Yoshio Hashizume; Masahito Yamada; Tetsuyuki Kitamoto; Gen Sobue
Journal:  Neuropathology       Date:  2006-12       Impact factor: 1.906

3.  Neuropathologic characteristics of spinal cord lesions in sporadic Creutzfeldt-Jakob disease.

Authors:  Yasushi Iwasaki; Mari Yoshida; Yoshio Hashizume; Tetsuyuki Kitamoto; Gen Sobue
Journal:  Acta Neuropathol       Date:  2005-09-21       Impact factor: 17.088

4.  Factors influencing the survival period in Japanese patients with sporadic Creutzfeldt-Jakob disease.

Authors:  Yasushi Iwasaki; Akio Akagi; Maya Mimuro; Tetsuyuki Kitamoto; Mari Yoshida
Journal:  J Neurol Sci       Date:  2015-06-30       Impact factor: 3.181

5.  Panencephalopathic type of Creutzfeldt-Jakob disease: primary involvement of the cerebral white matter.

Authors:  T Mizutani; A Okumura; M Oda; H Shiraki
Journal:  J Neurol Neurosurg Psychiatry       Date:  1981-02       Impact factor: 10.154

6.  Neuropathologic characteristics of brainstem lesions in sporadic Creutzfeldt-Jakob disease.

Authors:  Yasushi Iwasaki; Yoshio Hashizume; Mari Yoshida; Tetsuyuki Kitamoto; Gen Sobue
Journal:  Acta Neuropathol       Date:  2005-06-03       Impact factor: 17.088

7.  Relation between clinical findings and progression of cerebral cortical pathology in MM1-type sporadic Creutzfeldt-Jakob disease: proposed staging of cerebral cortical pathology.

Authors:  Yasushi Iwasaki; Shinsui Tatsumi; Maya Mimuro; Tetsuyuki Kitamoto; Yoshio Hashizume; Mari Yoshida
Journal:  J Neurol Sci       Date:  2014-04-13       Impact factor: 3.181

8.  Neuropathological diagnostic criteria for Creutzfeldt-Jakob disease (CJD) and other human spongiform encephalopathies (prion diseases).

Authors:  H Budka; A Aguzzi; P Brown; J M Brucher; O Bugiani; F Gullotta; M Haltia; J J Hauw; J W Ironside; K Jellinger
Journal:  Brain Pathol       Date:  1995-10       Impact factor: 6.508

Review 9.  Neuropathological stageing of Alzheimer-related changes.

Authors:  H Braak; E Braak
Journal:  Acta Neuropathol       Date:  1991       Impact factor: 17.088

10.  Clinicopathologic characteristics of five autopsied cases of dura mater-associated Creutzfeldt-Jakob disease.

Authors:  Yasushi Iwasaki; Maya Mimuro; Mari Yoshida; Yoshio Hashizume; Tetsuyuki Kitamoto; Gen Sobue
Journal:  Neuropathology       Date:  2008-02       Impact factor: 1.906

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.